This site uses cookies. By continuing to browse the site you are agreeing to our use of cookies.
List of medicinal products under additional monitoring
Human medicines European public assessment report (EPAR): Breyanzi, lisocabtagen...
Human medicines European public assessment report (EPAR): Lyrica, pregabalin, Da...
Human medicines European public assessment report (EPAR): Kavigale, sipavibart, ...
New Approach Methodologies EU-IN Horizon Scanning Report
Annex to 24-27 February 2025 CHMP Agenda
Agenda of the CHMP meeting 24-27 February 2025
Human medicines European public assessment report (EPAR): Revinty Ellipta, fluti...
Human medicines European public assessment report (EPAR): Relvar Ellipta, flutic...
Review of transparency rules for the EU Clinical Trials Information System (CTIS)
European Medicines Agency procedural advice for users of the centralised procedu...
European Medicines Agency procedural advice for users of the centralised procedu...
European Medicines Agency pre-authorisation procedural advice for users of the c...
European Medicines Agency pre-authorisation procedural advice for users of the c...
Human medicines European public assessment report (EPAR): Xeljanz, tofacitinib, ...
Marketing authorisation application (MAA) - pre-submission interactions form
Human medicines European public assessment report (EPAR): Neparvis, sacubitril,v...
Human medicines European public assessment report (EPAR): Entresto, sacubitril,v...
Orphan designation: Adeno-associated virus serotype 9 containing the human RPE65...